Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3918 open-label extension in paroxysmal nocturnal hemoglobinuria
2019-000130-20Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pozelimab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-emergent adverse events and Effect on intravascular hemolysis. Started Oct 2019; status: active.
02
Drugs
pozelimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2019-000130-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000130-20.